Intra-Cellular Therapies (ITCI) PT Cut to $29 at Leerink Partners Amid ITI-007 Failure

September 29, 2016 6:38 AM EDT
Get Alerts ITCI Hot Sheet
Price: $13.65 +3.33%

Rating Summary:
    5 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade ITCI Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Leerink Partners analyst Seamus Fernandez slashed his price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $29.00 (from $95.00) but maintained an Outperform rating on the disappointing result that ITCI's leading drug candidate, ITI-007, failed to separate from placebo in the second Ph 3 schizophrenia study. Neither the 60 nor the 20mg arm differed from placebo on the primary endpoint (PANSS) total score; however, the 4mg risperidone active control arm showed a significant improvement.

Fernandez commented, "ITCI mgmt attribute the study failure to an "unusually high" placebo response. Furthermore, mgmt indicated that with 2 out of the 3 large studies of ITI-007 in schizophrenia demonstrating clear efficacy (Ph2 and 1st Ph3 trials), the company will work with FDA to discuss next steps, including a pot'l regulatory path for ITI-007. We believe the after-market stock reaction, trading at near cash (~$13-14/shr; ~$442M cash and equivalent at the end of 2Q16), is overdone. With a pot'l option to file and Ph3 trials in other CNS indications underway (e.g., bipolar depression and behavior disturbances), we believe that ITI-007 should not be assumed dead as the stock price implies."

For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.

Shares of Intra-Cellular Therapies closed at $42.35 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

The Children's Investment Fund (TCI)

Add Your Comment